New perspectives on the toxicity of etoposide.

abstract：:This presentation represents consensus recommendations for the treatment of patients with Waldenstrom's macroglobulinemia (WM), which were prepared in conjunction with the second International Workshop held in Athens, Greece during September 2002. The faculty adopted the following statements for the management of pati...

journal_title：Seminars in oncology

authors： Gertz MA,Anagnostopoulos A,Anderson K,Branagan AR,Coleman M,Frankel SR,Giralt S,Levine T,Munshi N,Pestronk A,Rajkumar V,Treon SP

更新日期：2003-04-01 00:00:00

abstract：:The Department of Veterans Affairs (VA) has a strong track record providing high-quality, evidence-based care to cancer patients. In order to accelerate discoveries that will further improve care for Veterans with cancer, the VA has partnered with the Center for Translational Data Science at the University of Chicago ...

journal_title：Seminars in oncology

authors： Do N,Grossman R,Feldman T,Fillmore N,Elbers D,Tuck D,Dhond R,Selva L,Meng F,Fitzsimons M,Ajjarapu S,Ayandeh S,Hall R,Do S,Brophy M

更新日期：2019-01-01 00:00:00

abstract：:A phase II study was performed to investigate the tolerance and efficacy of the combination of docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France) and gemcitabine in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC). To date, 24 patients (five with stage IIIB and 19 with stage IV NSCLC...

journal_title：Seminars in oncology

authors： Georgoulias V,Kourousis C,Androulakis N,Kakolyris S,Dimopoulos MA,Bouros D,Papadimitriou C,Hatzakis K,Heras P,Kalbakis K,Kotsakis T,Vardakis N,Meramveliotakis N,Hatzidaki D

更新日期：1997-08-01 00:00:00

abstract：:In this feasibility study, a 3-hour infusion of 225 mg/m2 paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) was combined with carboplatin dosed to an area under the concentration-time curve of 6 to treat patients with stage T2N0, T1-2N1, or T3N0-1 (excluding superior sulcus tumors) non-small cell lung ca...

journal_title：Seminars in oncology

authors： Pisters KM,Kris MG,Bunn PA Jr,Johnson DH,Ruckdeschel JC,Crowley JJ,Ginsberg RJ

更新日期：1997-08-01 00:00:00

abstract：:Identification of tumor-, patient-, or treatment-related prognostic factors in renal carcinoma (RC) would allow the most appropriate application of current and future therapy to patients with this poorly responsive malignancy. Stage, including degree of lymph node and venous involvement, and grade remain the most powe...

journal_title：Seminars in oncology

authors： Rini BI,Vogelzang NJ

更新日期：2000-04-01 00:00:00

abstract：:Patients with advanced colorectal cancer were randomized to receive either fluorouracil (5-FU) 370 mg/m2 IV days 1 to 5 followed by weekly applications of 5-FU 600 mg/m2 or the same doses of 5-FU preceded by folinic acid 200 mg/m2. Because of toxicity, the weekly 5-FU dose in the combination treatment schedule was red...

journal_title：Seminars in oncology

authors： Steinke B,Günther E,Hirschmann WD,Sondern W,Koniczek KH,Wander HE,Natt F,Wagner T,Hinrichs HF,Werdier D

更新日期：1992-04-01 00:00:00

abstract：:Gene therapy has now become a standard experimental approach for treating cancers that have failed conventional therapies. As the understanding of the molecular nature of carcinogenesis develops, new approaches are being taken to directly target tumor cells, thus bypassing the difficulties of killing cells that are re...

journal_title：Seminars in oncology

authors： Freeman SM,Whartenby KA,Freeman JL,Abboud CN,Marrogi AJ

更新日期：1996-02-01 00:00:00

abstract：:Chemotherapy for prostate cancer currently has an established role in the treatment of hormone-refractory prostate cancer. There is strong evidence that combined modality treatment with androgen ablation in addition to radiotherapy provides a benefit above and beyond radiotherapy alone in patients with a poor prognosi...

journal_title：Seminars in oncology

authors： Sandler HM,Narayan S,Smith DC

更新日期：2003-08-01 00:00:00

abstract：:The epidemiologic studies relevant to the hypothesis that exposure to tamoxifen is associated with risk of cancer of the endometrium and perhaps other organs are described, summarized, and evaluated. One large body of data comes from the randomized trials of tamoxifen as a therapeutic agent against established breast ...

journal_title：Seminars in oncology

authors： MacMahon B

更新日期：1997-02-01 00:00:00

abstract：:The combination of gemcitabine and docetaxel exhibits good activity in the treatment of advanced breast cancer. Phase II trial response rates using 21- or 28-day schedules have ranged from 36% to 79% in patient populations with varying degrees of pretreatment. In studies of extensively pretreated anthracycline-resista...

journal_title：Seminars in oncology

authors： Fumoleau P

更新日期：2003-04-01 00:00:00

abstract：:Much recent debate has focused on the optimal classification of epithelial neuroendocrine tumors (NETs). Multiple different systems of terminology, grading, and staging have been proposed, and some systems combine elements of grade and stage into a single prognostic classification. Recently, national and international...

journal_title：Seminars in oncology

authors： Klimstra DS

更新日期：2013-02-01 00:00:00

abstract：:High-dose interferon alfa (IFN alfa) therapy induces an overall response rate of 25% to 30% in unselected patients with acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma. Up to 50% of patients with relatively preserved immune reactivity respond to treatment. However, when dosages of 20 x 10(6) units o...

journal_title：Seminars in oncology

authors： Krown SE

更新日期：1990-02-01 00:00:00

abstract：:The outcomes in young adults aged 20-39 with sarcoma tend to be inferior compared to those in children and adolescents. There are differences in sarcoma histotype distribution with age, such that pediatric-type tumors predominate in the 20- to 25-year-old group while more adult-type sarcomas occur in those aged 35-39 ...

journal_title：Seminars in oncology

authors： Soliman H,Ferrari A,Thomas D

更新日期：2009-06-01 00:00:00

abstract：:Preclinical studies with zoledronic acid (Zometa; Novartis Pharmaceuticals Corp, East Hanover, NJ) have shown its potential in malignant bone disease. Clinical studies in the treatment of hypercalcemia of malignancy have been completed, as have phase I and II trials in patients with cancer and pre-existing bone metast...

journal_title：Seminars in oncology

authors： Coleman RE,Seaman JJ

更新日期：2001-04-01 00:00:00

abstract：:Epigenetic alterations play a pivotal role in cancer development and progression. Pharmacologic reversion of such alterations is feasible, and second generation "epigenetic drugs" are in development and have been demonstrated to possess significant immunomodulatory properties. This knowledge, together with the availab...

journal_title：Seminars in oncology

authors： Covre A,Coral S,Di Giacomo AM,Taverna P,Azab M,Maio M

更新日期：2015-06-01 00:00:00

abstract：:We studied the pharmacokinetics of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin administered in combination to 21 patients with advanced non-small cell lung cancer. Paclitaxel was administered as a 24-hour intravenous infusion at doses of 135 to 200 mg/m2. Carboplatin, dosed to a tar...

journal_title：Seminars in oncology

authors： Kearns CM,Belani CP,Erkmen K,Zuhowski M,Hiponia D,Zacharski D,Engstrom C,Ramanathan R,Trenn MR,Aisner J

更新日期：1995-10-01 00:00:00

abstract：:Recent improvements in the management of people living with human immunodeficiency virus (HIV) disease in the United States have led to remarkable reductions in HIV-related morbidity and mortality. The Centers for Disease Control and Prevention recently reported substantial reductions in acquired immunodeficiency synd...

journal_title：Seminars in oncology

authors： Sherer R

更新日期：1998-04-01 00:00:00

abstract：:Multiple myeloma (MM) is a heterogeneous disease for which several new treatments are available. Much has been learned about its biology over the past 15 years. We now understand that there are various subtypes of the disease, each one associated with different outcomes and clinical pathological features. While a deta...

journal_title：Seminars in oncology

authors： Fonseca R,Monge J

更新日期：2013-10-01 00:00:00

abstract：:The ability to predict the biological behavior of breast tumors can allow selection of the optimum treatment and follow-up strategies. Conventionally, tumor size, lymph node metastases, and histopathologic features have been used to determine the risk of systemic relapse. The discovery of a number of specific genetic ...

journal_title：Seminars in oncology

authors： Dhingra K,Hortobagyi GN

更新日期：1996-08-01 00:00:00

abstract：:Small cell carcinoma (SCC) has become recognized as a distinct, though relatively infrequent, clinical pathology that occurs in multiple sites throughout the head and neck. Excluding cases that are considered to arise from skin, SCC in the head and neck has been found to develop in nearly all structures associated wit...

journal_title：Seminars in oncology

authors： Renner G

更新日期：2007-02-01 00:00:00

abstract：:Lung cancer is the leading cause of cancer death in the United States. Lung cancer is frequently encountered by the radiologist, whether the lung cancer is detected on a chest radiograph obtained in a symptomatic patient, or is an incidental finding. The radiologic workup of pulmonary lesions suspected of being lung c...

journal_title：Seminars in oncology

authors： Broderick LS,Tarver RD,Conces DJ Jr

更新日期：1997-08-01 00:00:00

abstract：:As a result of the increasing effectiveness of cancer screening and preventive interventions, ethical issues, as well as legal liabilities, are increasingly associated with cancer genetic testing. These issues include the possible "duty to warn" relatives of inherited cancer risk, the appropriateness of testing of chi...

journal_title：Seminars in oncology

authors： Offit K,Thom P

更新日期：2007-10-01 00:00:00

abstract：:Acute lymphoblastic leukemia (ALL) 5-year survival rates are approaching 90% in children and 50% in adults who are receiving contemporary risk-directed treatment protocols. Current efforts focus not only on further improving cure rate but also on patient quality of life. Hence, all protocols decrease or limit the use ...

journal_title：Seminars in oncology

authors： Pui CH,Thiel E

更新日期：2009-08-01 00:00:00

abstract：:Remarkable strides have been made in the management of infectious complications after bone marrow transplantation. Improved understanding of patterns of infection, the introduction of new antimicrobials, the advent of cytokines to enhance immune recovery, the development of better strategies to control graft-versus-ho...

journal_title：Seminars in oncology

authors： Wingard JR

更新日期：1993-10-01 00:00:00

abstract：:Navelbine (NVB) or 5' nor-anhydro-vinblastine was shown to present a broader antitumor activity and to induce fewer side effects than vinblastine (VBL) or vincristine (VCR). The possible mechanisms of these differences were analyzed with in vitro methods. At substoichiometric concentrations, the three drugs inhibit mi...

journal_title：Seminars in oncology

authors： Fellous A,Ohayon R,Vacassin T,Binet S,Lataste H,Krikorian A,Couzinier JP,Meininger V

更新日期：1989-04-01 00:00:00

abstract：:An overview of the causes, the clinical pictures and the management of obstruction in three major organ systems due to primary and secondary malignant neoplasms has been presented. Such obstruction often produces dramatic clinical pictures that require careful, appropriate, and often aggressive therapy if patients are...

journal_title：Seminars in oncology

authors： Sise JG,Crichlow RW

更新日期：1978-06-01 00:00:00

abstract：:Transitional cell carcinoma of the urothelium is a highly chemosensitive tumor. Combination chemotherapy can provide both palliation and a modest survival advantage in patients with advanced disease. As shown in a recent phase III trial, the new gold standard should be considered gemcitabine/cisplatin, although toxici...

journal_title：Seminars in oncology

authors： Carles J,Nogué M

更新日期：2001-06-01 00:00:00

abstract：:Intraoperative lymphatic mapping and selective lymphadenectomy for solid malignancies is a novel technique, having been introduced into surgical practice in the last 12 years. Dissemination of this technique among surgeons has followed a course similar to that found with the introduction of new laparoscopic techniques...

journal_title：Seminars in oncology

authors： Wilke LG

更新日期：2004-06-01 00:00:00

abstract：:Pancreatic neoplasms are morphologically and genetically heterogeneous and include a wide variety of tumors ranging from benign to malignant with an extremely poor clinical outcome. Our understanding of these pancreatic neoplasms has improved significantly with recent advances in cancer sequencing. Awareness of molecu...

journal_title：Seminars in oncology

authors： Rishi A,Goggins M,Wood LD,Hruban RH

更新日期：2015-02-01 00:00:00

abstract：:Distant metastasis is the major cause for therapeutic failures in Clinical oncology. Active immunotherapy in the adjuvant setting of patients with low tumor volume would contribute to further reduction of the remaining tumor and establish long-lasting immunity that could protect the patient from recurrence of disease....

journal_title：Seminars in oncology

authors： Gilboa E

更新日期：1996-02-01 00:00:00